drugset / Trial / NCT05064332

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

NCT05064332

Phase 1 Completed 10 enrolled Pfizer
Non-randomizedSequentialOpen-labelBasic science

Summary

This is a Phase 1, open label, fixed sequence study of the effect of multiple dose PF-06650833 on single dose OC PK in healthy female subjects.

Timeline

Start
2021-10-08
Primary completion
2021-12-16
Completion
2021-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject ZIMLOVISERTIB Small molecule 400 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral
Subject levonogestrel Unknown 150 ug Oral

Indications

No indication recorded.